Abstracts tagged "autoimmune diseases"

Abstract Number: 0909 • ACR Convergence 2025
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Marcus Hines¹, Timothy Borbet² and Sergei Koralov², ¹New York University Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center, New York
Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
Abstract Number: 0625 • ACR Convergence 2025
DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Meghan Nelson¹, Mary Horton², Joanne Nititham³, Jinoos Yazdany⁴, Maria Dall'Era⁵, Cristina Lanata³ and Lindsey Criswell², ¹NIH/NIAMS/NHGRI, Bethesda, MD, ²NIH/NHGRI, Bethesda, MD, ³NIH/NHGRI, Bethesda, ⁴UCSF, San Francisco, CA, ⁵Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) experience significant variability in clinical outcomes. Our current understanding of the causes of disease heterogeneity are limited, preventing…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 0361 • ACR Convergence 2025
Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
Mercedes Chan¹, Lori Tucker¹, Jude AlMasoud¹, Jaime Guzman², Andrea Human¹, David Cabral³, Angela How⁴, Wendy Wong⁵ and Jennifer Corpuz⁶, ¹BC Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁴UBC, Vancouver, BC, Canada, ⁵University of British Columbia, Surrey, BC, Canada, ⁶UBC, New Westminster, BC, Canada
Background/Purpose: Graduating from child and family-oriented to adult-oriented health care is a vulnerable time when youth with chronic disease drop out of, or disengage from,…
Abstract Number: 0264 • ACR Convergence 2025
Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
Mohamed Tharwat Hegazy, Rania Yacoub, Sarah Sheta, Rana Hussein Amin and Noha Khalil, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Vogt-Koyanagi-Harada disease (VKH) is a systemic disease that affects the central nervous system, ocular, and integumentary system. It causes bilateral granulomatous uveitis, dysacusia ranging…
Abstract Number: 0203 • ACR Convergence 2025
Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Sung Ik Cho¹, Jin Kyun Park², Hee Won Cho³, Eun Young Lee⁴, Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, ³Seoul National University, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Cytomegalovirus (CMV) infection is a well-recognized complication in immunocompromised individuals, yet there islimited evidence guiding surveillance strategies in patients with rheumatic diseases on immunosuppressants.…
Abstract Number: 0079 • ACR Convergence 2025
Association of Protein Arginine Deiminase 4 with the Myosin-9 Motor Complex
Fatemeh Neela Moadab, Farheen Shaikh, Xiaoxing Wang, cecilia mustelin, Ethan Le, Rayan Najjar, Jie An, Alison Bays and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Genetic association data, immunohistochemistry, and functional experiments implicate protein arginine deiminase 4 (PAD4) in the pathogenesis of rheumatoid arthritis (RA). This disease is characterized…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 2695 • ACR Convergence 2025
B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Carlo Tur¹, Markus Eckstein², Laura Bucci¹, Janina Auth³, Christina Bergmann¹, Simon Rauber⁴, Melanie Hagen¹, Danae-Mona Nöthling¹, Sebastian Böltz¹, Andreas Wirsching¹, Filippo Fagni⁵, Giulia Corte⁶, Panagiotis Garantziotis¹, Jule Taubmann⁷, jochen wacker¹, Andreas Ramming⁸, Maria Antonietta D'Agostino⁹, Arndt Hartmann¹⁰, Fabian Müller¹¹, Andreas Mackensen¹², Ricardo Grieshaber-Bouyer¹³, Georg Schett¹⁴, Aline Bozec¹ and Maria Gabriella Raimondo¹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ⁵Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁶- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹¹University Hospital of Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³University Hospital Erlangen, Erlangen, Germany, ¹⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Advanced protein-based therapies targeting B-cells, including glycoengineered CD20 monoclonal antibody obinutuzumab (OBI) and the CD19/CD3 T-cell engager blinatumumab (BLI), show promise for managing severe…
Abstract Number: 2579 • ACR Convergence 2025
Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
Richard Moore¹, Lihong Huo¹, Colin Koziel¹, Barry Stripp², Tiphanie Vogel³, Daniel Wallace⁴ and Caroline Jefferies⁵, ¹Cedars-Sinai, Beverly Hills, CA, ²Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Baylor College of Medicine, Houston, TX, ⁴Cedars Sinai Medical Center, Studio City, CA, ⁵Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: COPA syndrome is an autosomal dominant disease caused by missense mutations within the COPA gene. Typical onset begins during childhood with patients developing lung…
Abstract Number: 2459 • ACR Convergence 2025
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Milena Delai¹, Rachel Simon¹, Eduardo Mantovani Cardoso² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
Abstract Number: 2279 • ACR Convergence 2025
Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Koray Tascilar¹, Mikkel Ostergaard², Verena Schoenau³, Uta Kiltz⁴, Xenofon Baraliakos⁴, David Kofler⁵, Martin Feuchtenberger⁶, Ulrike Steffen⁷, Mario Zaiss⁸, Michael Zaenker⁹, Reinhard Voll¹⁰, Cornelia. Glaser¹¹, Holger Bang¹², Eugen feist¹³, Gerd Burmester¹⁴, Kirsten Karberg¹⁵, Joachim Strunk¹⁶, Juan Cañete¹⁷, Esperanza Naredo¹⁸, Mária Filková¹⁹, Ladislav Šenolt¹⁹, Georg Schett²⁰ and Juergen Rech⁷, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ³- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Cologne, Cologne, Germany, ⁶MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, Burghausen, Bayern, Germany, ⁷Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, ⁸¹Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, ⁹Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, Berlin, Germany, ¹⁰University Medical Center Freiburg, Freiburg, Germany, ¹¹Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Freiburg, Baden-Wurttemberg, Germany, ¹²Orgentec, Mainz, Germany, ¹³Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ¹⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹⁵Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, Berlin, Germany, ¹⁶Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Köln-Porz, Germany, ¹⁷Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁸Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, MADRID, Spain, ¹⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: A 6-month intervention with abatacept in the ARIAA trial (EUDRA-CT 2014–000555–93) significantly retarded the development of RA compared to placebo in ACPA-positive individuals with…
Abstract Number: 1967 • ACR Convergence 2025
Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging
Saahil Sachdeva¹, Briana Cervantes², Lisa Rider³ and Adam Schiffenbauer⁴, ¹NIEHS/NIBIB/NIH, Danville, CA, ²Department of Emergency Medicine, Norfolk, VA, ³National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁴National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle and skin inflammation. One potential complication of DM is calcinosis, the heterotopic calcification…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1649 • ACR Convergence 2025
Does Physical Activity Differ Among those with Autoimmune vs Non-Autoimmune Rheumatic Diseases?
Sydney Liles¹, Jennifer Copson², Yvonne Lee³ and Daniel K. White¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Wilmington, DE, ³Northwestern University, Chicago, IL
Background/Purpose: Individuals with rheumatic conditions, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA), often experience low physical activity levels. Physical activity may vary by autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].